University of Florida Health Pathology Laboratories’ GatorSeq next-generation sequencing (NGS) test panel represents a group of massively parallel, high-throughput DNA sequencing tests. Cancer-causing mutations often cluster in hotspots, where tumors from different patients harbor the same recurrent mutation. GatorSeq NGS allows for the testing a large number of clinically actionable hotspots simultaneously, allowing for the selection of the appropriate treatment for each patient.
GatorSeq NGS is a hybridization capture-based next-generation-targeted resequencing assay for deep sequencing of 1207 exons of 76 key cancer genes, encompassing 240,998bp of genomic DNA. Tumor samples are macrodissected to increase tumor cell percentage in the analyzed sample and sequenced on an Illumina NextSeq to high-uniform depth (targeting 500x coverage by non-polymerase chain reaction (PCR)-duplicate read pairs, with more than 99 percent of exons at coverage greater than 100 times). Sequence data are processed using a customized analysis pipeline that is designed to accurately detect base substitutions and insertions/deletions. Annotated reports are generated using a GenomeOncology-developed software and database.